Our innovative research programs in Pathology bridge multiple disciplines to pursue both fundamental and translational research. Our goals are to understand the basic molecular, cellular, and physiological mechanisms of disease and to continually translate our findings into improved patient care.
The fields of molecular pathology and diagnostics are being transformed by our researchers, whose investigations focus on unraveling the mechanisms of cancer progression and etiology of inflammatory and degenerative diseases. Strongest areas of expertise are: molecular biology, cell biology, genetics, virology, and vascular biology.
In a research article published in the journal Nature, Yale pathologists David Rimm, Emily Reisenbichler and colleagues investigated the PD-LI immunohistochemical assay, SP142, which recently received FDA approval. The assay is used as a companion test to determine eligibility for atezolizumab therapy in patients with advanced triple negative breast cancer (TNBC).
Yale Researchers ID Biomarkers Associated with PD-1 Checkpoint Blockade
David Rimm, Yale University Professor of Pathology, Director of Pathology Tissue Services & Director of Translational Pathology and his research team utilized digital spatial profiling technology to identify spatially-informed biomarkers’ response to PD-1 checkpoint blockade in patients with advanced non-small-cell lung cancer. The findings appear in “Biomarkers Associated With Beneficial PD-1 Checkpoint Blockade in Non-Small-Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling” in the American Association for Cancer Research journal.
Yale researchers, including David Rimm, professor of Pathology, Director of Pathology Tissue Services and Director of Translational Pathology, published a study that cast doubt on current Food and Drug Administration-approved screenings for biomarkers used to determine whether patients with advanced triple negative breast cancer (TNBC) will benefit from the immunotherapy drugs. Specifically, they considered patients deemed good candidates for the PD-L1 immunohistochemical assay, SP142, which was recently approved by FDA.
This article discusses the discovery and testing of Digital Spatial Profiling (“DSP”), which is an alternative PD-1 protein measurement system.
The research team utilized a “previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays.
Yale Developing Biologics to Treat Severe COVID-19 Symptoms
Demetrios Braddock, associate professor of Pathology, and his research team, will evaluate novel therapeutic biologics — drugs from living organisms — in treating severe COVID-19 infection in animal models. The success of these experiments may help alleviate the organ damage, renal failure, and Acute Respiratory Distress Syndrome (ARDS) experienced by severely infected COVID-19 patients.
Yale Researchers Create Atlas of Human Retina
Yale scientists have made an incredible genetic breakthrough by creating the first single-cell transcriptomic atlas of the human retina. They performed massively parallel single-cell RNA sequencing of the human retina using two independent platforms.
Yale Advances New Approach to Treat EGFR mutant Lung Cancer
A research team from Yale Pathology describes mechanisms of resistance to Osimertinib, a tyrosine kinase inhibitor used to treat EGFR mutant lung cancer (“EGFR”), in a study published in the journal Cancer Research. The team included first author and Pathology PhD student Jacqueline Starrett, co-author Robert Homer, professor of Pathology, and senior author Katerina Politi, associate professor of Pathology.